Health Care • Medical Specialities
$49.00 ▼ -1.01
(-2.02%)
MKT CAP: $4.02B • VOL: 1.15M
52W L $29 52W H $61
VCYT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $517.1M | $445.8M | $361.1M |
| YoY Revenue Growth % | +16.0% | +23.5% | — |
| Gross Profit | $362.5M | $298.1M | — |
| Gross Margin % | 70.1% | 66.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $57.8M | $16.1M | -$85.8M |
| Operating Margin % | 11.2% | 3.6% | -23.8% |
| Net Income (GAAP) | $66.4M | $24.1M | -$74.4M |
| EBITDA (Normalized) | $65.5M | $25.2M | -$72.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $136.3M | $75.1M | $44.2M |
| Capital Expenditures (CapEx) | $9.7M | $11.3M | $16.2M |
| Free Cash Flow (FCF) | $126.6M | $63.8M | $28.0M |
| FCF Margin % | 24.5% | 14.3% | 7.7% |
| Return on Invested Capital (ROIC %) | 4.6% | 1.3% | -4.9% |
| Cash & Short-Term Equivalents | $362.6M | $239.1M | — |
| Total Debt (Short + Long Term) | $43.4M | $55.8M | $539.8M |
| Total Stockholders' Equity | $1.31B | $1.18B | $1.11B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VCYT.